ETFChannel.com
BCRX Description — BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.

Company Name: 
BioCryst Pharmaceuticals Inc
Website: 
www.biocryst.com
Sector: 
Biotechnology
Number of ETFs Holding BCRX: 
30
Total Market Value Held by ETFs: 
$314,325,689.84
Total Market Capitalization: 
$2,401,000,000
% of Market Cap. Held by ETFs: 
13.09%
 ETF   BCRX Weight   BCRX Amount 
 XBI   1.05%   $70,836,226         
 VTI   0.01%   $69,269,298         
 IWM   0.11%   $51,473,464         
 VXF   0.04%   $31,916,212         
 VB   0.03%   $29,713,401         
 VBK   0.07%   $17,636,557         
 IWO   0.14%   $12,380,633         
 VHT   0.04%   $7,964,023         
 IWN   0.07%   $7,438,653         
 VTWO   0.10%   $5,554,623         
List of all 30 ETFs holding BCRX »
Quotes delayed 20 minutes

Email EnvelopeFree BCRX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (2.80 out of 4)
10th percentile
(ranked lower than approx. 90% of all stocks covered)

Analysts Forecast:
BCRX Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding BCRX | BioCryst Pharmaceuticals Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.